Seres Therapeutics, Takeda & more — 3 GI company key notes

Here are three updates on GI companies from the past week:

Advertisement

The FDA granted Seres Therapeutics’ SER-287 orphan drug designation. SER-287 treats pediatric ulcerative colitis.

The FDA approved Ferring Pharmaceutical’s Clenpiq, a low-volume colonoscopy prep solution.

Takeda appointed Toshio Fujimoto, MD, to serve as the general manager of the Health Innovation Park in Shonan, Japan.

More articles on gastroenterology:
GI leader to know: Dr. Essam Quraishi of Gastrointestinal & Liver Consultants
Stock market week-in-review for 5 large GI companies — Nov. 27 to Dec. 1
How AI is improving polyp detection

Advertisement

Next Up in GI & Endoscopy

  • Gastroenterologists are raising concerns about the CMS’ finalized payment policies, according to a joint statement from the American College of…

  • As gastroenterology evolves, leaders are reimagining how to deliver comprehensive, patient-centered care.  Dinesh Madhok, MD, CEO of Jacksonville, Fla.-based Borland…

  • The FDA has approved linaclotide (Linzess) capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation,…

Advertisement

Comments are closed.